New hope for kids with aggressive brain cancer: targeted drug trial launches
NCT ID NCT07206849
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 26 times
Summary
This study tests a drug called tovorafenib in children and young adults (ages 1 to 39) who have been newly diagnosed with a fast-growing brain tumor (high-grade glioma or DIPG) that has a specific genetic change. The goal is to see if the drug can help them live longer by targeting the altered pathway in their tumor. About 79 participants will receive the drug after radiation therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.